Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05615883
Other study ID # INT 148/19
Secondary ID IG 2017 Project
Status Recruiting
Phase N/A
First received
Last updated
Start date January 20, 2020
Est. completion date March 31, 2023

Study information

Verified date September 2022
Source Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Contact Licia Rivoltini, MD
Phone +3902/23903245
Email licia.rivoltini@istitutotumori.mi.it
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is designed to investigate the effects of ketogenic milieu induced by acute exercise as well as the effects of recurrent exercise bouts on functional status and the accumulation in peripheral blood of MDSCs and the consequent balance on antitumor immunity in melanoma patients.


Description:

The screening period starts once a patient has provided written informed consent to participate in the study and ends on the day of exercise initiation. Screening assessments have to be done within 28 days prior to exercise initiation. The informed consent will adhere to IRB/ERC requirements, applicable laws and regulations. After the sign of an informed consensus, patients will be assigned to a specific exercise program. The first series of patients will be assigned to the Acute Exercise Program (AEP group), the second series to the Chronic Exercise Program (CEP group). The protocol will be implemented in the time between diagnosis and surgical intervention without any delay in the therapeutic pathway. Basal evaluation: patient's life style will be investigated using the short version of Physical Activity Questionnaire (Italian version) and MeDiet questionnaire. Age, weight and eight will be registered for all patients. The Lean Body Mass will be measured by Dual Energy X-ray Absorptiometry (DEXA). A cardiorespiratory test will be performed to calculate an appropriate exercise intensity and subsequently the Six Minutes WalkingTest and the Comfortable Walking Speed test will be run before exercise protocol. In the CEP group the DEXA and the walking tests will be repeated after the end of exercise program. Exercise prescription: the physical exercise consists in walking at a brisk pace. In order to produce a constant metabolic stress in patients with different aerobic power, walking intensity will be prescribed in accordance with the method of the Heart Rate Reserve (HRR), ie difference between resting heart rate (HR-resting) and the heart rate corresponding to muscle's maximal oxygen uptake (HR-max). This prescribing method is based on the linear relationship between heart rate reserve and muscle workload calculated as a percentage of the difference between resting and maximum muscle oxygen consumption (VO2R%). The training intensity will be set to the 30% HRR, the lowest intensity that produces a training effect. To minimize the impact of the research protocol on the patient's therapeutic path, the investigators refrain from the execution of a Cardio Pulmonary Exercise Test and therefore opted for calculating the HR-max using the ACSM formula. Given the entry criteria of this study the investigators believe this choice will minimally affect the exercise-dose prescription and study results. Acute Exercise Protocol (AEP): The acute program consists in a single walking session on a treadmill lasting 80 minutes. The exercise session will begin with a 10-minute warm-up at the patient's self selected comfortable speed. On the ending of warm up, treadmill speed will be increased until reaching target HRR zone. Then the treadmill speed will be maintained stable throughout the exercise session. Cardiac workload will be monitored by a Sport-watch (Garmin Forerunner 35) and the walking biomechanics by a foot sensor (Garmin Running Dynamic Pod Sensore). Chronic Exercise Protocol (CEP): The chronic program consists in a walking session on a treadmill lasting 80 minutes (depending on the AEP results), repeated three time a week for three weeks. The walking intensity will be defined during a treadmill test performed before the beginning of the exercise program. Each exercise session will begin with a 10-minute warm-up at the patient's self selected comfortable speed. On the ending of warm up, patients will increase treadmill speed until reaching target HRR zone. Then the treadmill speed will be maintained stable throughout the exercise session. The first training session will be organized in hospital with supervision of research staff. Cardiac workload will be monitored by a Sport-watch(Garmin Forerunner 35) and walking biomechanics by a foot sensor (Garmin Running Dynamic Pod Sensore). Diet intervention: Modifications occurring during AEP strictly depend on the baseline metabolic conditions. For this reason, patients must remain fasting for 4 hours before the workout and avoid glucose rich foodies for 120 minutes after the end of exercise session in CEP group. During the exercise session patients will have free access to water only. All patients will complete a food diary during the study period.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date March 31, 2023
Est. primary completion date February 28, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Age from 18 to 65 years at the time of recruitment - Histologically confirmed diagnosis of primary melanoma - Patients who are candidate to curative surgery for primary melanoma, skin radicalization or sentinel node biopsy. - American Society of Anaesthesiologists (ASA) status I - Willingness and ability to comply with the protocol, the scheduled visits, treatment plans, laboratory tests and other procedures. - Understanding and signature of the informed consent - Female patients of childbearing potential must agree to sexual abstinence or to use highly effective method of contraception throughout the study (for CEP patients) Exclusion Criteria: - American Society of Anaesthesiologists (ASA) status > I - Pregnancy or lactation - Known infection from HIV virus - Regular physical exercise (more than 1 exercise workout of moderate to intense exercise activity per week) - Any physical or mental conditions interfering with the ability to perform exercise or to complete the testing procedures.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
AEP Group Walking Sessions
The AEP Program consists in a single walking session on a treadmill lasting 80 minutes
CEP Group Walking Sessions
The chronic program consists in a walking session on a treadmill lasting 80 minutes (depending on the AEP results), repeated three time a week for three weeks.

Locations

Country Name City State
Italy Fondazione IRCCS Istituto Nazionale dei Tumori Milan

Sponsors (1)

Lead Sponsor Collaborator
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Country where clinical trial is conducted

Italy, 

References & Publications (33)

ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002 Jul 1;166(1):111-7. Erratum in: Am J Respir Crit Care Med. 2016 May 15;193(10):1185. — View Citation

Ball D. Metabolic and endocrine response to exercise: sympathoadrenal integration with skeletal muscle. J Endocrinol. 2015 Feb;224(2):R79-95. doi: 10.1530/JOE-14-0408. Epub 2014 Nov 27. Review. — View Citation

Biswas SK. Metabolic Reprogramming of Immune Cells in Cancer Progression. Immunity. 2015 Sep 15;43(3):435-49. doi: 10.1016/j.immuni.2015.09.001. Review. — View Citation

Brooks GA, Mercier J. Balance of carbohydrate and lipid utilization during exercise: the "crossover" concept. J Appl Physiol (1985). 1994 Jun;76(6):2253-61. Review. — View Citation

Buck MD, Sowell RT, Kaech SM, Pearce EL. Metabolic Instruction of Immunity. Cell. 2017 May 4;169(4):570-586. doi: 10.1016/j.cell.2017.04.004. Review. — View Citation

Carruba G, Cocciadiferro L, Di Cristina A, Granata OM, Dolcemascolo C, Campisi I, Zarcone M, Cinquegrani M, Traina A. Nutrition, aging and cancer: lessons from dietary intervention studies. Immun Ageing. 2016 Apr 7;13:13. doi: 10.1186/s12979-016-0069-9. eCollection 2016. Review. — View Citation

Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, Knight SC, Yagita H, McCaffrey JC, Antonia S, Hockstein N, Witt R, Masters G, Bauer T, Gabrilovich DI. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis. J Clin Invest. 2014 Jun;124(6):2626-39. doi: 10.1172/JCI74056. Epub 2014 May 1. — View Citation

da Cunha FA, Farinatti Pde T, Midgley AW. Methodological and practical application issues in exercise prescription using the heart rate reserve and oxygen uptake reserve methods. J Sci Med Sport. 2011 Jan;14(1):46-57. doi: 10.1016/j.jsams.2010.07.008. Epub 2010 Sep 15. Review. — View Citation

Dazert E, Hall MN. mTOR signaling in disease. Curr Opin Cell Biol. 2011 Dec;23(6):744-55. doi: 10.1016/j.ceb.2011.09.003. Epub 2011 Sep 29. Review. — View Citation

Evans M, Cogan KE, Egan B. Metabolism of ketone bodies during exercise and training: physiological basis for exogenous supplementation. J Physiol. 2017 May 1;595(9):2857-2871. doi: 10.1113/JP273185. Epub 2016 Dec 7. Review. — View Citation

Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother. 2012 Feb;61(2):255-263. doi: 10.1007/s00262-011-1161-9. Epub 2011 Nov 27. Review. — View Citation

Fisher JS, Gao J, Han DH, Holloszy JO, Nolte LA. Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am J Physiol Endocrinol Metab. 2002 Jan;282(1):E18-23. — View Citation

Geiger PC, Wright DC, Han DH, Holloszy JO. Activation of p38 MAP kinase enhances sensitivity of muscle glucose transport to insulin. Am J Physiol Endocrinol Metab. 2005 Apr;288(4):E782-8. Epub 2004 Dec 7. — View Citation

Goodwin ML. Blood glucose regulation during prolonged, submaximal, continuous exercise: a guide for clinicians. J Diabetes Sci Technol. 2010 May 1;4(3):694-705. — View Citation

Jian SL, Chen WW, Su YC, Su YW, Chuang TH, Hsu SC, Huang LR. Glycolysis regulates the expansion of myeloid-derived suppressor cells in tumor-bearing hosts through prevention of ROS-mediated apoptosis. Cell Death Dis. 2017 May 11;8(5):e2779. doi: 10.1038/cddis.2017.192. — View Citation

Khaled YS, Ammori BJ, Elkord E. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol Cell Biol. 2013 Sep;91(8):493-502. doi: 10.1038/icb.2013.29. Epub 2013 Jun 25. Review. — View Citation

Li W, Tanikawa T, Kryczek I, Xia H, Li G, Wu K, Wei S, Zhao L, Vatan L, Wen B, Shu P, Sun D, Kleer C, Wicha M, Sabel M, Tao K, Wang G, Zou W. Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer. Cell Metab. 2018 Jul 3;28(1):87-103.e6. doi: 10.1016/j.cmet.2018.04.022. Epub 2018 May 24. — View Citation

Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab. 2014 Feb 4;19(2):181-92. doi: 10.1016/j.cmet.2013.12.008. Epub 2014 Jan 16. Review. — View Citation

Mann T, Lamberts RP, Lambert MI. Methods of prescribing relative exercise intensity: physiological and practical considerations. Sports Med. 2013 Jul;43(7):613-25. doi: 10.1007/s40279-013-0045-x. Review. — View Citation

McCulloch KL, Mercer V, Giuliani C, Marshall S. Development of a clinical measure of dual-task performance in walking: reliability and preliminary validity of the Walking and Remembering Test. J Geriatr Phys Ther. 2009;32(1):2-9. — View Citation

Motallebnezhad M, Jadidi-Niaragh F, Qamsari ES, Bagheri S, Gharibi T, Yousefi M. The immunobiology of myeloid-derived suppressor cells in cancer. Tumour Biol. 2016 Feb;37(2):1387-406. doi: 10.1007/s13277-015-4477-9. Epub 2015 Nov 26. Review. — View Citation

Murray B, Rosenbloom C. Fundamentals of glycogen metabolism for coaches and athletes. Nutr Rev. 2018 Apr 1;76(4):243-259. doi: 10.1093/nutrit/nuy001. Review. — View Citation

Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008 Oct;88(4):1379-406. doi: 10.1152/physrev.90100.2007. Review. — View Citation

Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 2009 Apr;9(4):285-93. doi: 10.1038/nrc2621. Review. — View Citation

Puchalska P, Crawford PA. Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. Cell Metab. 2017 Feb 7;25(2):262-284. doi: 10.1016/j.cmet.2016.12.022. Review. — View Citation

Purdom T, Kravitz L, Dokladny K, Mermier C. Understanding the factors that effect maximal fat oxidation. J Int Soc Sports Nutr. 2018 Jan 12;15:3. doi: 10.1186/s12970-018-0207-1. eCollection 2018. Review. — View Citation

Sawanobori Y, Ueha S, Kurachi M, Shimaoka T, Talmadge JE, Abe J, Shono Y, Kitabatake M, Kakimi K, Mukaida N, Matsushima K. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood. 2008 Jun 15;111(12):5457-66. doi: 10.1182/blood-2008-01-136895. Epub 2008 Mar 28. — View Citation

Swain DP, Franklin BA. VO(2) reserve and the minimal intensity for improving cardiorespiratory fitness. Med Sci Sports Exerc. 2002 Jan;34(1):152-7. — View Citation

Tanaka H, Monahan KD, Seals DR. Age-predicted maximal heart rate revisited. J Am Coll Cardiol. 2001 Jan;37(1):153-6. — View Citation

Trikha P, Plews RL, Stiff A, Gautam S, Hsu V, Abood D, Wesolowski R, Landi I, Mo X, Phay J, Chen CS, Byrd J, Caligiuri M, Tridandapani S, Carson W. Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator. Oncoimmunology. 2016 Jul 25;5(9):e1214787. eCollection 2016. — View Citation

Umansky V, Sevko A, Gebhardt C, Utikal J. Myeloid-derived suppressor cells in malignant melanoma. J Dtsch Dermatol Ges. 2014 Nov;12(11):1021-7. doi: 10.1111/ddg.12411. Epub 2014 Sep 28. Review. English, German. — View Citation

Wasserman DH. Four grams of glucose. Am J Physiol Endocrinol Metab. 2009 Jan;296(1):E11-21. doi: 10.1152/ajpendo.90563.2008. Epub 2008 Oct 7. Review. — View Citation

Yuan HX, Xiong Y, Guan KL. Nutrient sensing, metabolism, and cell growth control. Mol Cell. 2013 Feb 7;49(3):379-87. doi: 10.1016/j.molcel.2013.01.019. Review. — View Citation

* Note: There are 33 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Other Physical Activity Questionnaire Patient's life style will be investigated using the short version of Physical Activity Questionnaire Within one month of the enrollment
Other MeDiet questionnaire Patient's life style will be investigated using the short version of MeDiet questionnaire Within one month of the enrollment
Primary Quantification of the immune cell subsets (to determine if occur the re-setting antitumor immunity by short-term physical exercise) Immune cells will be analyzed for frequency and function by 10-color flow cytometry to test the reciprocal balance of protumor vs antitumor immune subsets. The analysis, based in the application of multiple panels of different antibodies, will be performed on peripheral blood mononuclear cells (PBMC) isolated from peripheral blood. AEP group: before exercise session.
Primary Quantification of the immune cell subsets (to determine if occur the re-setting antitumor immunity by short-term physical exercise) Immune cells will be analyzed for frequency and function by 10-color flow cytometry to test the reciprocal balance of protumor vs antitumor immune subsets. The analysis, based in the application of multiple panels of different antibodies, will be performed on peripheral blood mononuclear cells (PBMC) isolated from peripheral blood. AEP group: after 40 minutes of exercise session.
Primary Quantification of the immune cell subsets (to determine if occur the re-setting antitumor immunity by short-term physical exercise) Immune cells will be analyzed for frequency and function by 10-color flow cytometry to test the reciprocal balance of protumor vs antitumor immune subsets. The analysis, based in the application of multiple panels of different antibodies, will be performed on peripheral blood mononuclear cells (PBMC) isolated from peripheral blood. AEP group: after 80 minutes of exercise session.
Primary Quantification of the immune cell subsets (to determine if occur the re-setting antitumor immunity by short-term physical exercise) Immune cells will be analyzed for frequency and function by 10-color flow cytometry to test the reciprocal balance of protumor vs antitumor immune subsets. The analysis, based in the application of multiple panels of different antibodies, will be performed on peripheral blood mononuclear cells (PBMC) isolated from peripheral blood. AEP group: at 24 post-exercise.
Primary Quantification of the immune cell subsets (to determine if occur the re-setting antitumor immunity by short-term physical exercise) Immune cells will be analyzed for frequency and function by 10-color flow cytometry to test the reciprocal balance of protumor vs antitumor immune subsets. The analysis, based in the application of multiple panels of different antibodies, will be performed on peripheral blood mononuclear cells (PBMC) isolated from peripheral blood. AEP group: at 72 hours post-exercise.
Primary Quantification of the immune cell subsets (to determine if occur the re-setting antitumor immunity by short-term physical exercise) Immune cells will be analyzed for frequency and function by 10-color flow cytometry to test the reciprocal balance of protumor vs antitumor immune subsets. The analysis, based in the application of multiple panels of different antibodies, will be performed on peripheral blood mononuclear cells (PBMC) isolated from peripheral blood. CEP group: before exercise program.
Primary Quantification of the immune cell subsets (to determine if occur the re-setting antitumor immunity by short-term physical exercise) Immune cells will be analyzed for frequency and function by 10-color flow cytometry to test the reciprocal balance of protumor vs antitumor immune subsets. The analysis, based in the application of multiple panels of different antibodies, will be performed on peripheral blood mononuclear cells (PBMC) isolated from peripheral blood. CEP group: after one week of exercise program.
Primary Quantification of the immune cell subsets (to determine if occur the re-setting antitumor immunity by short-term physical exercise) Immune cells will be analyzed for frequency and function by 10-color flow cytometry to test the reciprocal balance of protumor vs antitumor immune subsets. The analysis, based in the application of multiple panels of different antibodies, will be performed on peripheral blood mononuclear cells (PBMC) isolated from peripheral blood. CEP group: up to two weeks of exercise program.
Primary Transcriptional Immune cell profiling (to determine if occur the re-setting antitumor immunity by short-term physical exercise) CD14+, CD15+ and total immune cells will be immunosorted directly from whole blood (3 ml) and frozen for the targeted expression profiling of signaling pathways and functional patterns (Nanostring or customized PCR cards). AEP group: before exercise.
Primary Transcriptional Immune cell profiling (to determine if occur the re-setting antitumor immunity by short-term physical exercise) CD14+, CD15+ and total immune cells will be immunosorted directly from whole blood (3 ml) and frozen for the targeted expression profiling of signaling pathways and functional patterns (Nanostring or customized PCR cards). AEP group: after 40 minutes of exercise session
Primary Transcriptional Immune cell profiling (to determine if occur the re-setting antitumor immunity by short-term physical exercise) CD14+, CD15+ and total immune cells will be immunosorted directly from whole blood (3 ml) and frozen for the targeted expression profiling of signaling pathways and functional patterns (Nanostring or customized PCR cards). AEP group: after 80 minutes of exercise session.
Primary Transcriptional Immune cell profiling (to determine if occur the re-setting antitumor immunity by short-term physical exercise) CD14+, CD15+ and total immune cells will be immunosorted directly from whole blood (3 ml) and frozen for the targeted expression profiling of signaling pathways and functional patterns (Nanostring or customized PCR cards). AEP group: at 24 post-exercise.
Primary Transcriptional Immune cell profiling (to determine if occur the re-setting antitumor immunity by short-term physical exercise) CD14+, CD15+ and total immune cells will be immunosorted directly from whole blood (3 ml) and frozen for the targeted expression profiling of signaling pathways and functional patterns (Nanostring or customized PCR cards). AEP group: at 72 hours post-exercise.
Primary Transcriptional Immune cell profiling (to determine if occur the re-setting antitumor immunity by short-term physical exercise) CD14+, CD15+ and total immune cells will be immunosorted directly from whole blood (3 ml) and frozen for the targeted expression profiling of signaling pathways and functional patterns (Nanostring or customized PCR cards). CEP group: before exercise program.
Primary Transcriptional Immune cell profiling (to determine if occur the re-setting antitumor immunity by short-term physical exercise) CD14+, CD15+ and total immune cells will be immunosorted directly from whole blood (3 ml) and frozen for the targeted expression profiling of signaling pathways and functional patterns (Nanostring or customized PCR cards). CEP group: after one week of exercise program.
Primary Transcriptional Immune cell profiling (to determine if occur the re-setting antitumor immunity by short-term physical exercise) CD14+, CD15+ and total immune cells will be immunosorted directly from whole blood (3 ml) and frozen for the targeted expression profiling of signaling pathways and functional patterns (Nanostring or customized PCR cards). CEP group: up to two weeks of exercise program.
Primary Analysis of the "systemic metabolic milieu"_AEPMet before In plasma we will quantify pH, Lactate, Ketone bodies, Free Fatty Acids, Glucose and Insulin serum levels that will be combined to report the metabolic parameters AEP group: before exercise.
Primary Analysis of the "systemic metabolic milieu"_AEPHor before In serum we will quantify ACTH, cortisol, epinephrine and norepinephrine concentrations that will be combined to report the hormonal parameters AEP group: before exercise.
Primary Analysis of the "systemic metabolic milieu"_AEPInf before In blood we will quantify IL-6, CRP, inflammatory cito/chemokines such as IL8, CCL2, IFN, IL10, IL1b, TNFa, TGFb that will be combined to report the inflammatory parameters AEP group: before exercise.
Primary Analysis of the "systemic metabolic milieu"_AEPLip before We will analyze the Lipidomics and amino acid profiles by laboratory test that will be combined to report the composition of cell membranes AEP group: before exercise.
Primary Analysis of the "systemic metabolic milieu"_AEPcounts before Whole blood cell counts will be also performed; this parameter is characterized by the absolute number as well as relative ratio. AEP group: before exercise.
Primary Analysis of the "systemic metabolic milieu"_AEPMet 40 In plasma we will quantify pH, Lactate, Ketone bodies, Free Fatty Acids, Glucose and Insulin serum levels that will be combined to report the metabolic parameters AEP group: after 40 minutes of exercise session.
Primary Analysis of the "systemic metabolic milieu"_AEPHor 40 In serum we will quantify ACTH, cortisol, epinephrine and norepinephrine concentrations that will be combined to report the hormonal parameters AEP group: after 40 minutes of exercise session.
Primary Analysis of the "systemic metabolic milieu"_AEPInf 40 In blood we will quantify IL-6, CRP, inflammatory cito/chemokines such as IL8, CCL2, IFN, IL10, IL1b, TNFa, TGFb that will be combined to report the inflammatory parameters AEP group: after 40 minutes of exercise session.
Primary Analysis of the "systemic metabolic milieu"_AEPLip 40 We will analyze the Lipidomics and amino acid profiles by laboratory test that will be combined to report the composition of cell membranes AEP group: after 40 minutes of exercise session.
Primary Analysis of the "systemic metabolic milieu"_AEPcounts 40 Whole blood cell counts will be also performed; this parameter is characterized by the absolute number as well as relative ratio. AEP group: after 40 minutes of exercise session.
Primary Analysis of the "systemic metabolic milieu"_AEPMet 80 In plasma we will quantify pH, Lactate, Ketone bodies, Free Fatty Acids, Glucose and Insulin serum levels that will be combined to report the metabolic parameters AEP group: after 80 minutes of exercise session.
Primary Analysis of the "systemic metabolic milieu"_AEPHor 80 In serum we will quantify ACTH, cortisol, epinephrine and norepinephrine concentrations that will be combined to report the hormonal parameters AEP group: after 80 minutes of exercise session.
Primary Analysis of the "systemic metabolic milieu"_AEPInf 80 In blood we will quantify IL-6, CRP, inflammatory cito/chemokines such as IL8, CCL2, IFN, IL10, IL1b, TNFa, TGFb that will be combined to report the inflammatory parameters AEP group: after 80 minutes of exercise session.
Primary Analysis of the "systemic metabolic milieu"_AEPLip 80 We will analyze the Lipidomics and amino acid profiles by laboratory test that will be combined to report the composition of cell membranes AEP group: after 80 minutes of exercise session.
Primary Analysis of the "systemic metabolic milieu"_AEPcounts 80 Whole blood cell counts will be also performed; this parameter is characterized by the absolute number as well as relative ratio. AEP group: after 80 minutes of exercise session.
Primary Analysis of the "systemic metabolic milieu"_AEPMet 24 In plasma we will quantify pH, Lactate, Ketone bodies, Free Fatty Acids, Glucose and Insulin serum levels that will be combined to report the metabolic parameters AEP group: at 24 post-exercise.
Primary Analysis of the "systemic metabolic milieu"_AEPHor 24 In serum we will quantify ACTH, cortisol, epinephrine and norepinephrine concentrations that will be combined to report the hormonal parameters AEP group: at 24 post-exercise.
Primary Analysis of the "systemic metabolic milieu"_AEPInf 24 In blood we will quantify IL-6, CRP, inflammatory cito/chemokines such as IL8, CCL2, IFN, IL10, IL1b, TNFa, TGFb that will be combined to report the inflammatory parameters AEP group: at 24 post-exercise.
Primary Analysis of the "systemic metabolic milieu"_AEPLip 24 We will analyze the Lipidomics and amino acid profiles by laboratory test that will be combined to report the composition of cell membranes AEP group: at 24 post-exercise.
Primary Analysis of the "systemic metabolic milieu"_AEPcounts 24 Whole blood cell counts will be also performed; this parameter is characterized by the absolute number as well as relative ratio. AEP group: at 24 post-exercise.
Primary Analysis of the "systemic metabolic milieu"_AEPMet 72 In plasma we will quantify pH, Lactate, Ketone bodies, Free Fatty Acids, Glucose and Insulin serum levels that will be combined to report the metabolic parameters AEP group: at 72 hours post-exercise.
Primary Analysis of the "systemic metabolic milieu"_AEPHor 72 In serum we will quantify ACTH, cortisol, epinephrine and norepinephrine concentrations that will be combined to report the hormonal parameters AEP group: at 72 hours post-exercise.
Primary Analysis of the "systemic metabolic milieu"_AEPInf 72 In blood we will quantify IL-6, CRP, inflammatory cito/chemokines such as IL8, CCL2, IFN, IL10, IL1b, TNFa, TGFb that will be combined to report the inflammatory parameters AEP group: at 72 hours post-exercise.
Primary Analysis of the "systemic metabolic milieu"_AEPLip 72 We will analyze the Lipidomics and amino acid profiles by laboratory test that will be combined to report the composition of cell membranes AEP group: at 72 hours post-exercise.
Primary Analysis of the "systemic metabolic milieu"_AEPcounts 72 Whole blood cell counts will be also performed; this parameter is characterized by the absolute number as well as relative ratio. AEP group: at 72 hours post-exercise.
Primary Analysis of the "systemic metabolic milieu"_CEPMet before In plasma we will quantify pH, Lactate, Ketone bodies, Free Fatty Acids, Glucose and Insulin serum levels that will be combined to report the metabolic parameters CEP group: before exercise program.
Primary Analysis of the "systemic metabolic milieu"_CEPHor before In serum we will quantify ACTH, cortisol, epinephrine and norepinephrine concentrations that will be combined to report the hormonal parameters CEP group: before exercise program.
Primary Analysis of the "systemic metabolic milieu"_CEPInf before In blood we will quantify IL-6, CRP, inflammatory cito/chemokines such as IL8, CCL2, IFN, IL10, IL1b, TNFa, TGFb that will be combined to report the inflammatory parameters CEP group: before exercise program.
Primary Analysis of the "systemic metabolic milieu"_CEPLip before We will analyze the Lipidomics and amino acid profiles by laboratory test that will be combined to report the composition of cell membranes CEP group: before exercise program.
Primary Analysis of the "systemic metabolic milieu"_CEP counts before Whole blood cell counts will be also performed; this parameter is characterized by the absolute number as well as relative ratio. CEP group: before exercise program.
Primary Analysis of the "systemic metabolic milieu"_CEPMet 1w In plasma we will quantify pH, Lactate, Ketone bodies, Free Fatty Acids, Glucose and Insulin serum levels that will be combined to report the metabolic parameters CEP group: after one week of exercise program.
Primary Analysis of the "systemic metabolic milieu"_CEPHor 1w In serum we will quantify ACTH, cortisol, epinephrine and norepinephrine concentrations that will be combined to report the hormonal parameters CEP group: after one week of exercise program.
Primary Analysis of the "systemic metabolic milieu"_CEPInf 1w In blood we will quantify IL-6, CRP, inflammatory cito/chemokines such as IL8, CCL2, IFN, IL10, IL1b, TNFa, TGFb that will be combined to report the inflammatory parameters CEP group: after one week of exercise program.
Primary Analysis of the "systemic metabolic milieu"_CEPLip 1w We will analyze the Lipidomics and amino acid profiles by laboratory test that will be combined to report the composition of cell membranes CEP group: after one week of exercise program.
Primary Analysis of the "systemic metabolic milieu"_CEPcounts 1w Whole blood cell counts will be also performed; this parameter is characterized by the absolute number as well as relative ratio. CEP group: after one week of exercise program.
Primary Analysis of the "systemic metabolic milieu"_CEPMet 2w In plasma we will quantify pH, Lactate, Ketone bodies, Free Fatty Acids, Glucose and Insulin serum levels that will be combined to report the metabolic parameters CEP group: up to two week of exercise program.
Primary Analysis of the "systemic metabolic milieu"_CEPHor 2w In serum we will quantify ACTH, cortisol, epinephrine and norepinephrine concentrations that will be combined to report the hormonal parameters CEP group: up to two week of exercise program.
Primary Analysis of the "systemic metabolic milieu"_CEPInf 2w In blood we will quantify IL-6, CRP, inflammatory cito/chemokines such as IL8, CCL2, IFN, IL10, IL1b, TNFa, TGFb that will be combined to report the inflammatory parameters CEP group: up to two week of exercise program.
Primary Analysis of the "systemic metabolic milieu"_CEPLip 2w We will analyze the Lipidomics and amino acid profiles by laboratory test that will be combined to report the composition of cell membranes CEP group: up to two week of exercise program.
Primary Analysis of the "systemic metabolic milieu"_CEPcounts 2w Whole blood cell counts will be also performed; this parameter is characterized by the absolute number as well as relative ratio. CEP group: up to two week of exercise program.
Primary Analysis of the metabolic parameters by capillary sampling_AEPCap before Capillary sampling (prick sampling) to analysis metabolic parameters at systemic blood level will be performed during the first, in-hospital, training session and further will be continued at home, self-managed by the patient who will have to measure glycaemia and ketones every morning (finger prick sampling) and after each training sessions (earlobe prick sampling). AEP group: before exercise session.
Primary Analysis of the metabolic parameters by capillary sampling_AEPCap 40 Capillary sampling (prick sampling) to analysis metabolic parameters at systemic blood level will be performed during the first, in-hospital, training session and further will be continued at home, self-managed by the patient who will have to measure glycaemia and ketones every morning (finger prick sampling) and after each training sessions (earlobe prick sampling). AEP group: after 40 minutes of exercise session.
Primary Analysis of the metabolic parameters by capillary sampling_AEPCap 80 Capillary sampling (prick sampling) to analysis metabolic parameters at systemic blood level will be performed during the first, in-hospital, training session and further will be continued at home, self-managed by the patient who will have to measure glycaemia and ketones every morning (finger prick sampling) and after each training sessions (earlobe prick sampling). AEP group: after 80 minutes of exercise session.
Primary Analysis of the metabolic parameters by capillary sampling_AEPCap 24 Capillary sampling (prick sampling) to analysis metabolic parameters at systemic blood level will be performed during the first, in-hospital, training session and further will be continued at home, self-managed by the patient who will have to measure glycaemia and ketones every morning (finger prick sampling) and after each training sessions (earlobe prick sampling). AEP group: at 24 post-exercise.
Primary Analysis of the metabolic parameters by capillary sampling_AEPCap 72 Capillary sampling (prick sampling) to analysis metabolic parameters at systemic blood level will be performed during the first, in-hospital, training session and further will be continued at home, self-managed by the patient who will have to measure glycaemia and ketones every morning (finger prick sampling) and after each training sessions (earlobe prick sampling). AEP group: at 72 hours post-exercise.
Primary Analysis of the metabolic parameters by capillary sampling_CEPCap before Capillary sampling (prick sampling) to analysis metabolic parameters at systemic blood level will be performed during the first, in-hospital, training session and further will be continued at home, self-managed by the patient who will have to measure glycaemia and ketones every morning (finger prick sampling) and after each training sessions (earlobe prick sampling). CEP group: during the first training session
Primary Analysis of the metabolic parameters by capillary sampling_CEPCap 2w Capillary sampling (prick sampling) to analysis metabolic parameters at systemic blood level will be performed during the first, in-hospital, training session and further will be continued at home, self-managed by the patient who will have to measure glycaemia and ketones every morning (finger prick sampling) and after each training sessions (earlobe prick sampling). CEP group: every morning up to two weeks.
Primary Analysis of the metabolic parameters by capillary sampling_CEPCap end Capillary sampling (prick sampling) to analysis metabolic parameters at systemic blood level will be performed during the first, in-hospital, training session and further will be continued at home, self-managed by the patient who will have to measure glycaemia and ketones every morning (finger prick sampling) and after each training sessions (earlobe prick sampling). CEP group: at the end of training sessions up to two weeks.
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT03979872 - Risk Information and Skin-cancer Education for Undergraduate Prevention N/A
Recruiting NCT04986748 - Using QPOP to Predict Treatment for Sarcomas and Melanomas
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05707286 - Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT05470283 - Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma Phase 1
Recruiting NCT05077137 - A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy Phase 1
Active, not recruiting NCT02721459 - XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma Phase 1
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT05839912 - Excision of Lymph Node Trial (EXCILYNT) (Mel69) N/A
Recruiting NCT04971499 - A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05263453 - HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation Phase 2
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Completed NCT03348891 - TNF in Melanoma Patients Treated With Immunotherapy N/A
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT03171064 - Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment Phase 2
Not yet recruiting NCT05539118 - Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma Phase 1/Phase 2
Recruiting NCT05171374 - pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
Withdrawn NCT02854488 - Yervoy Pregnancy Surveillance Study